drugset / Trial / NCT02131480

Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma

NCT02131480

Phase 2 Completed 110 enrolled Gustave Roussy, Cancer Campus, Grand Paris
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Uterine leiomyosarcomas and soft tissues are rare tumors with a poor prognosis when metastatic or locally advanced. They have an average chemosensitivity mainly to doxorubicin, ifosfamide, cisplatin, gemcitabine and trabectedin but response rates in combination in first line does not exceed 55% for uterine leiomyosarcomas and 35% for leiomyosarcomas of soft tissue. The trabectedin is a new cancer drug that has obtained marketing authorization after failure of anthracyclines and ifosfamide in the treatment of soft tissue sarcomas (STM) in Europe. It has especially shown efficacy in myxoid liposarcomas, leiomyosarcomas and synoviosarcoma. This study aims to evaluate the usefulness of the combination of trabectedin with doxorubicin in first-line treatment of uterine or soft tissue leiomyosarcoma.

Timeline

Start
2010-06
Primary completion
2013-01
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 60 mg/m2 Intravenous
Subject Trabectedin Small molecule 1.1 mg/m2 Intravenous

Indications